Objective — to investigate the efficiency of combined therapy with Panavir in patients with anogenital (venereal) warts on the basis of assessment of the patients’ clinical data and recurrence rates following the treatment performed. Subject and methods. Fifty-eight patients diagnosed with anogenital (venereal) warts were examined. Group 1 (n=29) underwent cryodestruction of pathological lesions; Group 2 (n=29) had cryodestruction when using various Panavir formulations: rectal suppositories at day 1 of treatment for 10 days or vaginal suppositories and external gel at day 5 of therapy (after cryodestruction) for 10 days. Results. During monotherapy with Panavir (rectal suppositories) prior to destruction, there was a decline in the number and extent of anogenital warts (in 10.3% of patients) and a reduction in the intensity or absence of itching, burning, and pain in the area of rashes (in 37.9% of patients). At 6 days of destruction, there was complete tissue epithelialization in 21 (72.4%) patients in Group 1 and 29 (100%) in Group 2 and no subjective manifestations in 9 (31.1%) and 27 (93.3%) patients, respectively. Within 90 days of follow-up, no disease recurrence was recorded in 22 (75.9%) patients of Group 1 and in 27 (93.1%) in Group 2. Conclusion. Combined therapy performed in patients with clinical manifestations of human papillomavirus infection, by using the systemic and topical formulations of Panavir, demonstrates its high efficiency, prevention of disease recurrence, good tolerance in patients, and the absence of side effects and complications during drug use.